GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Medicenna Therapeutics Corp (OTCPK:MDNAF) » Definitions » Cyclically Adjusted Price-to-FCF

MDNAF (Medicenna Therapeutics) Cyclically Adjusted Price-to-FCF : (As of Jun. 03, 2025)


View and export this data going back to 2017. Start your Free Trial

What is Medicenna Therapeutics Cyclically Adjusted Price-to-FCF?

Shiller PE for Stocks: The True Measure of Stock Valuation


Medicenna Therapeutics Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for Medicenna Therapeutics's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Medicenna Therapeutics Cyclically Adjusted Price-to-FCF Chart

Medicenna Therapeutics Annual Data
Trend Dec15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Medicenna Therapeutics Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Medicenna Therapeutics's Cyclically Adjusted Price-to-FCF

For the Biotechnology subindustry, Medicenna Therapeutics's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Medicenna Therapeutics's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Medicenna Therapeutics's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Medicenna Therapeutics's Cyclically Adjusted Price-to-FCF falls into.


;
;

Medicenna Therapeutics Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

Medicenna Therapeutics's Cyclically Adjusted FCF per Share for the fiscal year that ended in Mar24 is calculated as:

For example, Medicenna Therapeutics's adjusted Free Cash Flow per Share data for the fiscal year that ended in Mar24 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Mar24 (Change)*Current CPI (Mar24)
=-0.172/126.2576*126.2576
=-0.172

Current CPI (Mar24) = 126.2576.

Medicenna Therapeutics Annual Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201512 0.000 99.947 0.000
201603 -0.122 101.054 -0.152
201703 -0.323 102.634 -0.397
201803 -0.321 105.004 -0.386
201903 -0.234 106.979 -0.276
202003 -0.122 107.927 -0.143
202103 -0.245 110.298 -0.280
202203 -0.343 117.646 -0.368
202303 -0.143 122.702 -0.147
202403 -0.172 126.258 -0.172

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Medicenna Therapeutics  (OTCPK:MDNAF) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


Medicenna Therapeutics Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of Medicenna Therapeutics's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Medicenna Therapeutics Business Description

Traded in Other Exchanges
Address
2 Bloor Street W., 7th Floor, Toronto, ON, CAN, M4W 3E2
Medicenna Therapeutics Corp is a Canada-based immuno-oncology company. Its principal business activity is the development and commercialization of IL-2, IL-4, and IL13 Superkines and Empowered Superkines for the treatment of cancer and other diseases. Its pipeline candidates include MDNA55 for recurrent glioblastoma multiforme (rGBM), MDNA11 for Cancer immunotherapies, MDNA209 for Autoimmune Diseases, MDNA413 for Cancer immunotherapies, and MDNA132 for Solid Tumors, BiSKITs represents the novel platform comprised of Bifunctional SuperKine ImmunoTherapies.

Medicenna Therapeutics Headlines

From GuruFocus